Nyxoah Signs MoU with Sheikh Shakhbout Medical City for Middle East Genio Implant Program
Nyxoah signed a memorandum of understanding with Sheikh Shakhbout Medical City Hospital in the UAE to expand Genio hypoglossal nerve stimulation therapy with a high-volume implant program. The deal also designates SSMC as a Middle East training hub for surgeons, sleep physicians and supports research on OSA and metabolic diseases.
1. Memorandum of Understanding Details
Nyxoah formalized a strategic partnership with Sheikh Shakhbout Medical City Hospital in Abu Dhabi via a memorandum of understanding to expand its Genio hypoglossal nerve stimulation therapy across the Middle East. The agreement aligns Nyxoah with a flagship PureHealth subsidiary renowned for treating serious and complex conditions.
2. High-Volume Implant Program
Under the MoU, Nyxoah and SSMC will establish a high-volume Genio implant program aimed at increasing patient access and supporting the development of standardized surgical protocols. The program is designed around patient-centered care to drive procedural efficiency and volume growth.
3. Regional Training Hub
The collaboration designates SSMC as a regional training hub for Genio therapy, where surgeons, sleep physicians and referring healthcare professionals from across the Middle East will receive hands-on instruction and education. This initiative is intended to build local expertise and ensure consistent clinical outcomes.
4. Clinical Research Collaboration
Nyxoah and SSMC will explore joint clinical research initiatives focusing on obstructive sleep apnea management and its impact on chronic and metabolic diseases such as type 2 diabetes. These studies aim to generate data on Genio’s therapeutic benefits and support future treatment guidelines.